Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 43Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 17Colorectal Neoplasms 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Sarcoma 11Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Triple Negative Breast Neoplasms 10Lung Neoplasms 10Cholangiocarcinoma 10Esophageal Squamous Cell Carcinoma 9Esophageal Neoplasms 9Osteosarcoma 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Neoplasms 6Head and Neck Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Liver Neoplasms 5Glioma 5Drug-Related Side Effects and Adverse Reactions 4Thyroid Neoplasms 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

fludarabine phosphate 26Etoposide 23Peripheral Blood Stem Cell Transplantation 22pegaspargase 21Whole-Body Irradiation 21Mycophenolic Acid 20Cyclophosphamide 19Busulfan 17Gemcitabine 16Dexamethasone 16Tacrolimus 15Methotrexate 15Cyclosporine 12Radiotherapy 11Antilymphocyte Serum 11Melphalan 8Asparaginase 8Rituximab 7Oxaliplatin 7Flow Cytometry 6Therapeutics 5Lenalidomide 5Bortezomib 5thymoglobulin 4spartalizumab 4Transplantation 4Polymerase Chain Reaction 4Panobinostat 4Methylprednisolone 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Extranodal NK-T-Cell × apatinib × Clear all
NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Peking University

Phase 2 Unknown
61 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡